Leeward Investments LLC MA Cuts Stock Holdings in Hologic, Inc. $HOLX

Leeward Investments LLC MA trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 163,443 shares of the medical equipment provider’s stock after selling 3,172 shares during the period. Leeward Investments LLC MA owned 0.07% of Hologic worth $10,650,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Victory Capital Management Inc. grew its stake in Hologic by 34.4% during the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock valued at $408,283,000 after acquiring an additional 1,692,177 shares in the last quarter. Invesco Ltd. grew its stake in Hologic by 18.8% during the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock valued at $298,655,000 after acquiring an additional 764,573 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Hologic by 1.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider’s stock valued at $276,303,000 after acquiring an additional 69,878 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Hologic by 0.8% during the first quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider’s stock valued at $216,973,000 after acquiring an additional 29,133 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Hologic by 8.1% during the first quarter. Dimensional Fund Advisors LP now owns 2,838,656 shares of the medical equipment provider’s stock valued at $175,331,000 after acquiring an additional 213,366 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

Hologic stock opened at $73.99 on Friday. The firm has a market cap of $16.46 billion, a P/E ratio of 30.70, a P/E/G ratio of 2.54 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39. The business’s fifty day moving average is $67.65 and its two-hundred day moving average is $63.99.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business’s revenue was up 1.2% on a year-over-year basis. During the same period last year, the business earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on HOLX shares. Evercore ISI set a $78.00 price objective on shares of Hologic and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. BTIG Research reissued a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. Wall Street Zen lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, October 1st. Finally, Leerink Partners lifted their target price on shares of Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $79.23.

Insiders Place Their Bets

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction on Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the transaction, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.88% of the stock is owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.